Avid Logo June 2022.jpg
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024
April 24, 2024 17:25 ET | Avid Bioservices, Inc
-- Recorded Third Quarter Revenue of $33.8 Million -- -- Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million -- -- Celebrated Completion of Recent Expansion...
Biolojic.Design_Logo_vertical_color - resized.jpg
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
April 24, 2024 07:00 ET | Biolojic Design
Nektar Therapeutics Has Exercised Its License Option to Develop Biolojic Design's AI-Designed Antibody Targeting TNFR2 in Immunology
logo.png
Biologics Market Size Expected to Reach USD 845.78 Billion by 2033
March 12, 2024 11:20 ET | Precedence Research
Ottawa, March 12, 2024 (GLOBE NEWSWIRE) -- The global biologics market size was valued at USD 419.07 billion in 2023 and is projected to surpass around USD 698.17 billion by 2031, a study published...
Avid Logo June 2022.jpg
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
March 06, 2024 23:58 ET | Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing...
Avid Logo June 2022.jpg
Avid Bioservices Announces Proposed Private Placement of Convertible Notes
March 06, 2024 16:32 ET | Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it...
Avid Logo June 2022.jpg
Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024
March 06, 2024 16:31 ET | Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Research Nester Logo.jpg
Biologics Contract Development & Manufacturing Organization Market revenue to hit USD 39 Billion by 2036, says Research Nester
February 08, 2024 05:30 ET | Research Nester
New York, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The global biologics contract development & manufacturing organization (CDMO) market size is projected to grow at a CAGR of over ~12% from 2024 to...
84bd90f5-4a1f-42a8-8eb1-5cb062a0b6ac.png
Prefilled Syringes Market Size to Surpass USD 72.9 Billion by 2033 Owing to the Increasing Prevalence of Chronic Diseases
January 22, 2024 13:30 ET | Market.Us
New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- According to Market.us, the Global Prefilled Syringes Market size is forecasted to exceed US$ 72.9 Billion by 2033, with a promising CAGR of 12.3% from...
logo.png
Biologics Market Size Estimated to Reach USD 620.31 Billion by 2032
January 08, 2024 11:15 ET | Precedence Research
Ottawa, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The global biologics market size accounted for USD 387.73 billion in 2024, grew to USD 409.84 billion in 2025 and the industry is expanding at a CAGR of 6%...
Xcellent Insights Logo.png
Biologics Market Growth CAGR 6.9% During 2023-2032 | Xcellent Insights
January 03, 2024 03:00 ET | XCELLENT INSIGHTS LLP
Pune, Jan. 03, 2024 (GLOBE NEWSWIRE) -- The global biologics market is expected to register a rapid revenue CAGR of 6.9% during the forecast period. This growth can be attributed to factors such...